JPRN-UMIN000004345已完成未知
Phase II clinical trial of the combination of high-dose toremifene and exemestane for advanced/recurrent breast cancer unresponsive to nonsteroidal aromatase inhibitors - Phase II clinical trial of the combination of high-dose toremifene and exemestane for advanced/recurrent breast cancer unresponsive to nonsteroidal aromatase inhibitors
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1. Patients with active double cancer 2. Patients with life-threatening symptoms, extensive organ metastasis (1/3 of the organ), or brain metastasis 3. Patients with a past history of severe drug hypersensitivity 4. Pregnant or breastfeeding females 5. Other patients who were considered by the primary care physician to be inappropriate as subjects of this trial
研究者
相似试验
已完成
2 期
Phase 2 trial of first-line combination therapy of cisplatin, pemetrexed and nivolumab in participants with unresectable malignant pleural mesotheliomamalignant pleural mesotheliomaJPRN-UMIN000030892Okayama Rosai Hospital18
进行中（未招募）
不适用
Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not receive high-dose chemotherapy.EUCTR2014-001620-29-ESGrupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL)77
已完成
2 期
Phase II clinical trial of combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary diseaseCOPDJPRN-UMIN000015222ational Hospital Organization Toneyama National Hospital10
进行中（未招募）
不适用
A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanomaadvanced BRAF V600 mutant melanomaMedDRA version: 16.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10066600Term: Melanoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004966-33-BEZ Brussel
已完成
2 期
Phase II clinical study of the combination chemotherapy regimen of topotecan plus oral etoposide for the treatment of recurrent ovarian cancerResistant ovarian cancerJPRN-UMIN000007318Kyorin University, School of Medicine20